Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of "Buy" by Analysts

Key Points

• Consensus "Buy": Twelve analysts cover Definium Therapeutics with a consensus Buy rating (1 sell, 9 buy, 2 strong buy) and an average 12‑month price target of $35.70, with several firms recently raising targets (e.g., HC Wainwright to $70, RBC to $36).
• Institutional buying: Multiple hedge funds increased positions (Commodore Capital 5.0M shares, Marshall Wace 3.42M, Vanguard 2.01M), and institutional ownership stands at about 27.91%.
• Company and stock snapshot: Definium is a clinical‑stage brain‑health biopharma with lead candidates MM120 (Phase 3 for GAD/ADHD) and DT402 (Phase 2a for autism); shares recently traded near $20.68, with a 52‑week range of $4.70–$21.10 and a market cap of ~$2.06B.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $35.70.

DFTX has been the subject of a number of analyst reports. Robert W. Baird set a $37.00 price target on Definium Therapeutics in a report on Thursday, January 29th. HC Wainwright raised their price objective on Definium Therapeutics from $55.00 to $70.00 and gave the company a "buy" rating in a report on Monday, March 2nd. Jefferies Financial Group assumed coverage on Definium Therapeutics in a research report on Thursday, January 29th. They issued a "buy" rating and a $30.00 price objective for the company. Wolfe Research assumed coverage on Definium Therapeutics in a research note on Monday, February 23rd. They set an "outperform" rating and a $25.00 target price for the company. Finally, Royal Bank Of Canada increased their target price on Definium Therapeutics from $20.00 to $36.00 and gave the company an "outperform" rating in a research report on Friday, January 23rd.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Commodore Capital LP increased its stake in shares of Definium Therapeutics by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company's stock worth $32,450,000 after purchasing an additional 475,000 shares in the last quarter. Marshall Wace LLP raised its position in shares of Definium Therapeutics by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company's stock worth $22,204,000 after purchasing an additional 828,067 shares during the last quarter. Vanguard Group Inc. lifted its stake in Definium Therapeutics by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company's stock valued at $23,732,000 after buying an additional 198,878 shares in the last quarter. AWM Investment Company Inc. boosted its holdings in Definium Therapeutics by 0.6% in the 2nd quarter. AWM Investment Company Inc. now owns 1,215,662 shares of the company's stock worth $7,890,000 after buying an additional 7,500 shares during the last quarter. Finally, Rosalind Advisors Inc. boosted its holdings in Definium Therapeutics by 78.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company's stock worth $8,842,000 after buying an additional 330,000 shares during the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Stock Performance

DFTX stock opened at $20.68 on Friday. The company's 50-day simple moving average is $17.74 and its 200-day simple moving average is $14.38. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. Definium Therapeutics has a 52-week low of $4.70 and a 52-week high of $21.10. The firm has a market cap of $2.06 billion, a P/E ratio of -9.71 and a beta of 2.44.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.